<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00979368</url>
  </required_header>
  <id_info>
    <org_study_id>MB124-001</org_study_id>
    <nct_id>NCT00979368</nct_id>
  </id_info>
  <brief_title>Safety Study of BMS-816336 in Healthy Male Subjects</brief_title>
  <official_title>Randomized, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BMS-816336 in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics
      following single oral doses of BMS-816336 in healthy male subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Exposure to the investigational drug will be measured to assess safety and tolerability</measure>
    <time_frame>Within 72 hours following dosing</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the single dose Pharmacokinetics of BMS-816336</measure>
    <time_frame>During 72 hours following dosing</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Diabetes Mellitus, Non-Insulin-Dependent</condition>
  <condition>Dyslipidemia</condition>
  <arm_group>
    <arm_group_label>BMS-816336 or placebo (Panel 1)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BMS-816336 or placebo (Panel 2)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BMS-816336 or placebo (Panel 3)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BMS-816336 or placebo (Panel 4)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BMS-816336 or placebo (Panel 5)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-816336</intervention_name>
    <description>Suspension, Oral, 15 mg Active, Once on Day 1 only, 4 days</description>
    <arm_group_label>BMS-816336 or placebo (Panel 1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-816336</intervention_name>
    <description>Suspension, Oral, 60 mg Active, Once on Day 1 only, 4 days</description>
    <arm_group_label>BMS-816336 or placebo (Panel 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-816336</intervention_name>
    <description>Suspension, Oral, 180 mg Active, Once on Day 1 only, 4 days</description>
    <arm_group_label>BMS-816336 or placebo (Panel 3)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-816336</intervention_name>
    <description>Suspension, Oral, 450 mg Active, Once on Day 1 only, 4 days</description>
    <arm_group_label>BMS-816336 or placebo (Panel 4)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-816336</intervention_name>
    <description>Suspension, Oral, 900 mg Active, Once on Day 1 only, 4 days</description>
    <arm_group_label>BMS-816336 or placebo (Panel 5)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Suspension, Oral, 0 mg, Once on Day 1 only, 4 days</description>
    <arm_group_label>BMS-816336 or placebo (Panel 1)</arm_group_label>
    <arm_group_label>BMS-816336 or placebo (Panel 2)</arm_group_label>
    <arm_group_label>BMS-816336 or placebo (Panel 3)</arm_group_label>
    <arm_group_label>BMS-816336 or placebo (Panel 4)</arm_group_label>
    <arm_group_label>BMS-816336 or placebo (Panel 5)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male subjects

          -  BMI of 18 to 32 kg/m²

          -  Men only, ages 18-55 years

        Exclusion Criteria:

          -  Sexually active men not using effective birth control if their partners are WOCBP

          -  Any significant acute or chronic medical illness

          -  Family history of Gilbert's disease

          -  History of Pancreatitis

          -  Evidence of organ dysfunction or any clinically significant deviation from normal in
             physical examination, vital signs, EGG or clinical laboratory determinations

          -  QTc interval &gt; 450 msec (corrected for heart rate using Fridericia's correction
             method, QTcF)

          -  Second- or third-degree A-V block or clinically relevant ECG abnormalities

          -  History of allergy to 11-β-HSD-1 inhibitors or related compounds

          -  Prior exposure to BMS-816336

          -  Use of St. John's Wort (Hypericum) within 4 weeks prior to the first dose of study
             drug and throughout the study

          -  Use of an oral, injectable, inhalable or suspension of glucocorticoid agents within 12
             weeks of study drug administration

          -  Use of any glucocorticoid topical creams within 4 weeks of study drug administration

          -  Use of oral, injectable, or topical androgen agent within 12 weeks prior to enrollment
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>For FDA Safety Alerts and Recalls refer to the following link: http://www.fda.gov/MEDWATCH/safety.htm</description>
  </link>
  <verification_date>October 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 17, 2009</study_first_submitted>
  <study_first_submitted_qc>September 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 18, 2009</study_first_posted>
  <last_update_submitted>February 22, 2011</last_update_submitted>
  <last_update_submitted_qc>February 22, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 23, 2011</last_update_posted>
  <responsible_party>
    <name_title>Study Director</name_title>
    <organization>Bristol-Myers Squibb</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

